tert-butyl (3S)-3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate | 1204677-53-1

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (3S)-3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate
• 英文别名: (S)-Tert-butyl 3-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate
• CAS: 1204677-53-1
• 化学式: C₁₂H₂₂N₂O₄
• 分子量: 258.318
• InChiKey: LAAAMOQBIKIHLV-VIFPVBQESA-N

物化性质

• 沸点：
  326.2±52.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S)-3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate 在 甲醇 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 (3S)-3-(1-hydroxy-3-methyl-butyl)-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of a Potent, Dual Serotonin and Norepinephrine Reuptake Inhibitor

  摘要：

  The objective of the described research effort was to identify novel serotonin and norepinephrine reuptake inhibitor (SNRI) with improved norepinephrine transporter activity and acceptable metabolic stability and exhibiting minimal drug-drug interaction. We describe herein the discovery of a series of 3-substituted pyrrolidines exemplified by compound 1. Compound 1 is a selective SNRI in vitro and in vivo has favorable ADME properties, and retains inhibitory activity in the formalin model of pain behavior. Compound 1 thus represents a potential new probe to explore utility of SNRIs in central nervous system disorders, including,chronic: pain conditions.

  DOI：

  10.1021/ml400049p
• 作为产物：
  描述：

  1-Boc-吡咯烷-3-甲酸甲酯 在 水 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 aq. phosphate buffer 、 二氯甲烷 为溶剂， 反应 73.0h， 生成 tert-butyl (3S)-3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of a Potent, Dual Serotonin and Norepinephrine Reuptake Inhibitor

  摘要：

  The objective of the described research effort was to identify novel serotonin and norepinephrine reuptake inhibitor (SNRI) with improved norepinephrine transporter activity and acceptable metabolic stability and exhibiting minimal drug-drug interaction. We describe herein the discovery of a series of 3-substituted pyrrolidines exemplified by compound 1. Compound 1 is a selective SNRI in vitro and in vivo has favorable ADME properties, and retains inhibitory activity in the formalin model of pain behavior. Compound 1 thus represents a potential new probe to explore utility of SNRIs in central nervous system disorders, including,chronic: pain conditions.

  DOI：

  10.1021/ml400049p

文献信息

• [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE UTILISÉS EN TANT QUE BLOQUEURS DES CANAUX POTASSIQUES KV1.3 DE TYPE SHAKER
  申请人：DE SHAW RES LLC

  公开号：WO2021071806A1

  公开（公告）日：2021-04-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

  描述了化合物的公式（I）或其药学上可接受的盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用该药物的方法。
• SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
  申请人：Su Wei-Guo

  公开号：US20140121200A1

  公开（公告）日：2014-05-01

  Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the specification.

  提供了式（1）的吡啶吡嗪化合物，以及其药物组合物和使用方法，其中R1、R2、R3、R4和m如规范中所定义。
• [EN] SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS<br/>[FR] PYRIDOPYRAZINES SUBSTITUÉES EN TANT QUE NOUVEAUX INHIBITEURS DE SYK
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2012167423A1

  公开（公告）日：2012-12-13

  Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.

  提供了某些吡啶吡嗪化合物，其药物组成物以及使用方法。
• 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS
  申请人：Stangeland Eric

  公开号：US20100022616A1

  公开（公告）日：2010-01-28

  In one aspect, the invention relates to compounds of formula I: where a and R 1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  在一个方面，该发明涉及到以下式I的化合物：其中a和R1-6如规范中所定义，或其药用可接受盐。式I的化合物是血清素和去甲肾上腺素再摄取抑制剂。在另一个方面，该发明涉及到包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的工艺和中间体。
• SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR
  申请人：DREYFUS Nicolas Jacques Francois

  公开号：US20100261762A1

  公开（公告）日：2010-10-14

  A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.

  一种谷胺酸和去甲肾上腺素的再摄取抑制剂的配方：描述了其用途和制备方法。